Global Vision Holdings Inc. Cl B (GVHIB) 0.0017 $GVHIB
Global Vision Holdings Inc. Reports Growth for Subsidiary: The Place Media
ACCESSWIRE - Wed Jul 30, 12:50PM CDT
IRVINE, CA / ACCESSWIRE / July 30, 2014 / Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
Global Vision Holdings Inc. (OTCQB: GVHIB) is a Diversified Financial Holding Company Focusing on Investments in Environmentally Responsible, Profitable and Growing Companies
ACCESSWIRE - Thu Jul 24, 6:58PM CDT
IRVINE, CA / ACCESSWIRE / July 24, 2014 / Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
eTeligis - Thu Jul 24, 6:50PM CDT
IRVINE, CA, United States, via eTeligis Inc., 07/24/2014 - - Mama's Best, a subsidiary of Global Vision, produces high quality organic sauces, marinades, soups, and spreads. After the incredible response of rolling out Mama's Best jams to Sprouts and Whole Foods, the consumer response exploded. This has lead Mama's Best into a new research and development stage of their company. The company is focusing on 5-10 new products such as five soups, two chimichurri sauces, four salad dressings and additional products. Glen Carnes, CEO and Chairman of Global Vision Holdings, Inc., which owns Mamma's Best, states "I am enthusiastic to roll out more of Mama's Best Products to it's consumers. We value the loyalty of our customer base and I look forward to sharing our products with the shopper."
PharmaPoint Report: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022
M2 - Tue Feb 04, 9:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvp3hs/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. The US is the largest hemophilia market, due to the high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. Companies such as Baxter, Bayer, Novo Nordisk, CSL Behring and Biogen Idec will be able to command slight premiums over currently marketed recombinant standard of care therapies, thus contributing to overall market growth. Scope - Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitive Assessment 5.3 Product Profiles - Major Brands, Hemophilia A 5.4 Product Profiles - Hemophilia B 5.5 Product Profiles - Hemophilia A and B with Inhibitors 6 Opportunity and Unmet Need 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development - Hemophilia A 7.3 Promising Drugs in Clinical Development - Hemophilia B 7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/jv...harmapoint
Whitebox Advisors Adds Jon Olstein in Strategic Relationships Role
PR Newswire - Thu Jan 23, 1:00PM CST
Today, Whitebox Advisors, an asset management company based in Minneapolis with over $3 billion in AUM (12/31/2013), announced the addition of Jon Olstein as a managing director for strategic relationships based in the New York/Tri-state area.
Global Vision Holdings Inc. Reports Growth for Subsidiary: The Place Media
ACCESSWIRE - Wed Jul 30, 12:50PM CDT
IRVINE, CA / ACCESSWIRE / July 30, 2014 / Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
Global Vision Holdings Inc. (OTCQB: GVHIB) is a Diversified Financial Holding Company Focusing on Investments in Environmentally Responsible, Profitable and Growing Companies
ACCESSWIRE - Thu Jul 24, 6:58PM CDT
IRVINE, CA / ACCESSWIRE / July 24, 2014 / Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
Global Vision Holdings Inc. (OTCQB: GVHIB) is a diversified financial holding company focusing on investments in environmentally responsible, profitable and growing companies.
eTeligis - Thu Jul 24, 6:50PM CDT
IRVINE, CA, United States, via eTeligis Inc., 07/24/2014 - - Mama's Best, a subsidiary of Global Vision, produces high quality organic sauces, marinades, soups, and spreads. After the incredible response of rolling out Mama's Best jams to Sprouts and Whole Foods, the consumer response exploded. This has lead Mama's Best into a new research and development stage of their company. The company is focusing on 5-10 new products such as five soups, two chimichurri sauces, four salad dressings and additional products. Glen Carnes, CEO and Chairman of Global Vision Holdings, Inc., which owns Mamma's Best, states "I am enthusiastic to roll out more of Mama's Best Products to it's consumers. We value the loyalty of our customer base and I look forward to sharing our products with the shopper."
PharmaPoint Report: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022
M2 - Tue Feb 04, 9:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvp3hs/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. The US is the largest hemophilia market, due to the high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. Companies such as Baxter, Bayer, Novo Nordisk, CSL Behring and Biogen Idec will be able to command slight premiums over currently marketed recombinant standard of care therapies, thus contributing to overall market growth. Scope - Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitive Assessment 5.3 Product Profiles - Major Brands, Hemophilia A 5.4 Product Profiles - Hemophilia B 5.5 Product Profiles - Hemophilia A and B with Inhibitors 6 Opportunity and Unmet Need 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development - Hemophilia A 7.3 Promising Drugs in Clinical Development - Hemophilia B 7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/jv...harmapoint
Whitebox Advisors Adds Jon Olstein in Strategic Relationships Role
PR Newswire - Thu Jan 23, 1:00PM CST
Today, Whitebox Advisors, an asset management company based in Minneapolis with over $3 billion in AUM (12/31/2013), announced the addition of Jon Olstein as a managing director for strategic relationships based in the New York/Tri-state area.
